All relevant data is available within the Dryad Repository at DOI: [10.5061/dryad.m0cfxpp0g](https://doi.org/10.5061/dryad.m0cfxpp0g).

Introduction {#sec005}
============

Activating mutations of *BRAF* and *NRAS* are the most common mutations observed in melanoma. They are present in approximately 51--63% and 26--28% respectively of the molecular mutations in melanomas \[[@pone.0230306.ref001],[@pone.0230306.ref002]\]. Accordingly, the prognostic implications of these mutations are well characterized \[[@pone.0230306.ref003]\]. Both *BRAF* mutations (*BRAF*^*mut*^) and *NRAS* mutations (*NRAS*^*mut*^) have been shown to be early events that occur in benign and pre-invasive lesions and are not sufficient to induce carcinogenesis \[[@pone.0230306.ref004],[@pone.0230306.ref005]\]. Rather, an accumulation of additional pathogenic mutations is required for pre-malignant *BRAF*^*mut*^ or *NRAS*^*mut*^ lesions to progress to invasive melanoma \[[@pone.0230306.ref004]\].

Mitogenic driver mutations such as *BRAF* and *NRAS* induce senescence in premalignant disease and require secondary mutations in cell cycle control genes to convert *BRAF* and *NRAS* aberrations into oncogenes \[[@pone.0230306.ref004],[@pone.0230306.ref006]--[@pone.0230306.ref009]\]. Loss of function mutations of *CDKN2A* and *TP53* are two significant genomic alterations that allow oncogene driven melanocytes to overcome senescence and evade apoptosis \[[@pone.0230306.ref010],[@pone.0230306.ref011]\]. Given the importance of TP53 and *CDKN2A* mutations in the pathogenesis of invasive melanoma it is understandable that both of these mutations are common mutations in melanoma. According to The Cancer Genome Atlas (TCGA) data genomic alterations of *TP53* and *CDKN2A* are found in 15.1% and 13.3% of melanomas respectively \[[@pone.0230306.ref002]\], and are are frequently co-mutated with *BRAF* and *NRAS* mutations. When *CDKN2A* mutations are present they are found to be co-mutated with *BRAF*, *NRAS* and non-*NRAS*/*BRAF* mutations at rates of 33.3% - 67.4%, 23.9% - 40.7% and 8.7% - 29.9% respectively \[[@pone.0230306.ref002],[@pone.0230306.ref012]\]. Similarly *TP53* is co-mutated with *BRAF*, *NRAS* and non-*BRAF*/*NRAS* mutations with frequencies of 33.1% - 73.9%, 17.4% - 35.7% and 8.7% - 32.2% respectively. *CDKN2A* and *TP53* mutations were present together in 5.5% - 8.3% of cases. *BRAF*, *NRAS*, *CDKN2A* and *TP53* mutations were absent in 8.3% - 32.2% of cases.

Historically both *TP53* and *CDKN2A* mutations are associated with a poor prognosis in melanoma patients. Several studies have shown that patients with *TP53* or *CDKN2A* mutations have a shorter expected survival \[[@pone.0230306.ref013]--[@pone.0230306.ref015]\]. This occurs, at least in part, because *TP53* and *CDKN2A* mutated tumors are more resistant to chemotherapy \[[@pone.0230306.ref013]\]. Several preclinical studies have demonstrated that *TP53* and *CDKN2A* mutations lead to a loss of normal cell cycle regulation which in turn causes malignant cells to develop chemoresistance \[[@pone.0230306.ref016],[@pone.0230306.ref017]\]. This paradigm of poor outcomes and chemoresistance is pervasive and has been demonstrated in multiple other malignancies. This is further supported by the observation that the use of cyclin-dependent kinase (CDK) inhibitors can enhance responsiveness to chemotherapy in tumors with loss of P16^INK4a^ \[CDKN2A loss of function mutation\] \[[@pone.0230306.ref018],[@pone.0230306.ref019]\]. However, it is not clear that this paradigm remains true in melanoma with the era of checkpoint inhibitors.

Neither *BRAF* nor *NRAS* mutations are thought to directly impact the efficacy of immunotherapy; however, previous studies have demonstrated nuances in response rates with checkpoint inhibitors according to genotypes. Douglas *et al* were the first to report the influence of *NRAS*^*mut*^ on immunotherapy outcomes and concluded that individuals harboring *NRAS*^*mut*^ had improved response rates, clinical benefit and progression free survival \[[@pone.0230306.ref020]\]. However, this study included all subtypes of melanoma and also only contained a small cohort of patients who received programmed death-1 (PD-1) inhibitors. Kim *et al* subsequently published a study assessing the effects of *TP53* and non-V600 BRAF mutations (*BRAF*^*non-v600*^) on clinical outcomes of cutaneous melanomas \[[@pone.0230306.ref021]\]. Neither *TP53* nor *BRAF*^*non-v600*^ mutations were associated with overall survival (OS) with ipilumumab treatment. There is a paucity of literature discussing the clinical outcomes of patients with *CDKN2A* and *TP53* mutations since the introduction of immune checkpoint inhibitors. Herein we report the effect of *TP53* and *CDKN2A* mutations on the response to immune checkpoint inhibitors, including PD1 inhibitors, in patients with advanced cutaneous melanoma and melanoma of unknown primary.

Results {#sec006}
=======

Mutational status and patient characteristics {#sec007}
---------------------------------------------

A total of 207 melanoma patients had genomic profiling using our in house 50 gene panel, of which 102 patients met the inclusion criteria for this analysis ([Fig 1](#pone.0230306.g001){ref-type="fig"}). Genomic profiling was performed between March 1, 2014 and October 1, 2016. Clinical data were collected between January 1, 1990 and April 7, 2017. Of the 102 patients evaluated 14 (13.7%) patients were identified to have *CDKN2A*^*mut*^, 21 (20.6%) had *TP53*^*mut*^, and 12 (11.8%) were *Quad*^*WT*^; the genotypes of *CDKN2A*^*mut*^, *TP53*^*mut*^ and *Quad*^*WT*^ patients are displayed in [S1 Fig](#pone.0230306.s001){ref-type="supplementary-material"}. The patient characteristics for this cohort of patients are summarized in [Table 1](#pone.0230306.t001){ref-type="table"}.

![Flow diagram of patient selection.](pone.0230306.g001){#pone.0230306.g001}

10.1371/journal.pone.0230306.t001

###### Patient characteristics stratified by TP53 and CDKN2A mutations.

![](pone.0230306.t001){#pone.0230306.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          TP53^mut^      TP53^WT^       *P* Value                                     CDKN2A^mut^    CDKN2A^WT^     *P* Value                                     Quad^WT^       Not Quad WT    P Value
  ----------------------------------------------------------------------- -------------- -------------- --------------------------------------------- -------------- -------------- --------------------------------------------- -------------- -------------- --------------------------------------------
  **Age at diagnosis**                                                                                  0.83 [^a^](#t001fn001){ref-type="table-fn"}                                 0.50 [^a^](#t001fn001){ref-type="table-fn"}                                 0.15[^a^](#t001fn001){ref-type="table-fn"}

   Median                                                                 60.7           62.3                                                         63.9           61.2                                                         71.9           60.8           

   Range                                                                  (32.4--82.2)   (22.8--91.0)                                                 (31.6--88.5)   (22.8--91.0)                                                 (41.3--77.3)   (22.8--91.0)   

  **Gender**                                                                                            0.74 [^b^](#t001fn002){ref-type="table-fn"}                                 0.87 [^b^](#t001fn002){ref-type="table-fn"}                                 0.67[^b^](#t001fn002){ref-type="table-fn"}

   Male                                                                   14 (66.7%)     57 (70.4%)                                                   10 (71.4%)     61 (69.3%)                                                   9 (75.0%)      62 (68.9%)     

   Female                                                                 7 (33.3%)      24 (29.6%)                                                   4 (28.6%)      27 (30.7%)                                                   3 (25.0%)      28 (31.1%)     

  **Ethnicity**                                                                                         0.05 [^b^](#t001fn002){ref-type="table-fn"}                                 0.69 [^b^](#t001fn002){ref-type="table-fn"}                                 0.71[^b^](#t001fn002){ref-type="table-fn"}

   Caucasian                                                              20 (95.2%)     81 (100.0%)                                                  14 (100.0%)    87 (98.9%)                                                   12 (100.0%)    89 (98.9%)     

   Hispanic                                                               1 (4.8%)       0 (0%)                                                       0 (0%)         1 (1.1%)                                                     0 (0%)         1 (1.1%)       

  **Sites of Disease**                                                                                                                                                                                                                                          

   CNS                                                                    3 (16.7%)      20 (26.7%)     0.38 [^b^](#t001fn002){ref-type="table-fn"}   3 (23.1%)      20 (25.0%)     0.88 [^b^](#t001fn002){ref-type="table-fn"}   4 (36.4%)      19 (23.2%)     0.34[^b^](#t001fn002){ref-type="table-fn"}

   Liver                                                                  5 (27.8%)      19 (25.3%)     0.83 [^b^](#t001fn002){ref-type="table-fn"}   5 (38.5%)      19 (23.8%)     0.26 [^b^](#t001fn002){ref-type="table-fn"}   5 (45.5%)      19 (23.2%)     0.11[^b^](#t001fn002){ref-type="table-fn"}

   Lung                                                                   10 (55.6%)     37 (49.3%)     0.64 [^b^](#t001fn002){ref-type="table-fn"}   8 (61.5%)      39 (48.8%)     0.39 [^b^](#t001fn002){ref-type="table-fn"}   9 (81.8%)      38 (46.3%)     0.03[^b^](#t001fn002){ref-type="table-fn"}

   Adrenal                                                                1 (5.6%)       6 (8.0%)       0.72 [^b^](#t001fn002){ref-type="table-fn"}   2 (15.4%)      5 (6.3%)       0.25 [^b^](#t001fn002){ref-type="table-fn"}   1 (9.1%)       6 (7.3%)       0.83[^b^](#t001fn002){ref-type="table-fn"}

   Bone                                                                   4 (22.2%)      16 (21.3%)     0.93 [^b^](#t001fn002){ref-type="table-fn"}   0 (0%)         20 (25.0%)     0.04 [^b^](#t001fn002){ref-type="table-fn"}   2 (18.2%)      18 (22.0%)     0.78[^b^](#t001fn002){ref-type="table-fn"}

   Skin                                                                   2 (11.1%)      16 (21.3%)     0.32 [^b^](#t001fn002){ref-type="table-fn"}   0 (0%)         18 (22.5%)     0.06 [^b^](#t001fn002){ref-type="table-fn"}   1 (9.1%)       17 (20.7%)     0.36[^b^](#t001fn002){ref-type="table-fn"}

   Lymph Node                                                             8 (44.4%)      33 (44.0%)     0.97 [^b^](#t001fn002){ref-type="table-fn"}   7 (53.8%)      34 (42.5%)     0.44 [^b^](#t001fn002){ref-type="table-fn"}   6 (54.5%)      35 (42.7%)     0.46[^b^](#t001fn002){ref-type="table-fn"}

   Other                                                                  4 (25.0%)      20 (29.0%)     0.75 [^b^](#t001fn002){ref-type="table-fn"}   6 (50.0%)      18 (24.7%)     0.07 [^b^](#t001fn002){ref-type="table-fn"}   1 (10.0%)      23 (30.7%)     0.17[^b^](#t001fn002){ref-type="table-fn"}

  **Melanoma Subtype**                                                                                  0.10 [^b^](#t001fn002){ref-type="table-fn"}                                 0.80 [^b^](#t001fn002){ref-type="table-fn"}                                 0.41[^b^](#t001fn002){ref-type="table-fn"}

   Cutaneous                                                              15 (71.4%)     70 (86.4%)                                                   12 (85.7%)     73 (83.0%)                                                   11 (91.7%)     74 (82.2%)     

   Unknown Primary                                                        6 (28.6%)      11 (13.6%)                                                   2 (14.3%)      15 (17.0%)                                                   1 (8.3%)       16 (17.8%)     

  **Metastases**                                                                                        0.32 [^b^](#t001fn002){ref-type="table-fn"}                                 0.81 [^b^](#t001fn002){ref-type="table-fn"}                                 0.95[^b^](#t001fn002){ref-type="table-fn"}

   Yes                                                                    18 (85.7%)     75 (92.6%)                                                   13 (92.9%)     80 (90.9%)                                                   11 (91.7%)     82 (91.1%)     

   No                                                                     3 (14.3%)      6 (7.4%)                                                     1 (7.1%)       8 (9.1%)                                                     1 (8.3%)       8 (8.9%)       

  **Name of Therapy**                                                                                   0.14 [^b^](#t001fn002){ref-type="table-fn"}                                 0.68 [^b^](#t001fn002){ref-type="table-fn"}                                 0.03[^b^](#t001fn002){ref-type="table-fn"}

   Pembrolizumab                                                          7 (33.3%)      46 (56.8%)                                                   8 (57.1%)      45 (51.1%)                                                   7 (58.3%)      46 (51.1%)     

   Nivolumab                                                              1 (4.8%)       5 (6.2%)                                                     0 (0%)         6 (6.8%)                                                     3 (25.0%)      3 (3.3%)       

   Ipilimumab                                                             11 (52.4%)     23 (28.4%)                                                   5 (35.7%)      29 (33.0%)                                                   2 (16.7%)      32 (35.6%)     

   Nivolumab/Ipilimumab                                                   2 (9.5%)       3 (3.7%)                                                     0 (0%)         5 (5.7%)                                                     0 (0%)         5 (5.6%)       

   Other therapy                                                          0 (0%)         4 (4.9%)                                                     1 (7.1%)       3 (3.4%)                                                     0 (0%)         4 (4.4%)       

  **Other Therapy Name**                                                                                \-                                                                          \-                                                                          \-

   Ipilimumab/Dabrafenib                                                  0 (0%)         1 (25.0%)                                                    0 (0.0%)       1 (33.3%)                                                    0 (0%)         1 (25.0%)      

   Ipilimumab/Dacarbazine                                                 0 (0%)         1 (25.0%)                                                    1 (100.0%)     0 (0%)                                                       0 (0%)         1 (25.0%)      

   Pembrolizumab/Indoximod                                                0 (0%)         2 (50.0%)                                                    0 (0.0%)       2 (66.7%)                                                    0 (0%)         2 (50.0%)      

  **Lines of Therapy**                                                                                  0.84 [^b^](#t001fn002){ref-type="table-fn"}                                 0.43 [^b^](#t001fn002){ref-type="table-fn"}                                 0.87[^b^](#t001fn002){ref-type="table-fn"}

   1                                                                      18 (85.7%)     68 (84.0%)                                                   12 (85.7%)     74 (84.1%)                                                   11 (91.7%)     75 (83.3%)     

   2                                                                      3 (14.3%)      10 (12.3%)                                                   1 (7.1%)       12 (13.6%)                                                   1 (8.3%)       12 (13.3%)     

   3                                                                      0 (0%)         1 (1.2%)                                                     0 (0%)         1 (1.1%)                                                     0 (0%)         1 (1.1%)       

   4                                                                      0 (0%)         2 (2.5%)                                                     1 (7.1%)       1 (1.1%)                                                     0 (0%)         2 (2.2%)       

  **LDH elevated** [^c^](#t001fn003){ref-type="table-fn"}                                               0.45 [^b^](#t001fn002){ref-type="table-fn"}                                 0.06 [^b^](#t001fn002){ref-type="table-fn"}                                 0.09[^b^](#t001fn002){ref-type="table-fn"}

   Yes                                                                    2 (10.5%)      16 (21.6%)                                                   1 (8.3%)       17 (21.0%)                                                   4 (33.3%)      14 (17.3%)     

   No                                                                     13 (68.4%)     40 (54.1%)                                                   5 (41.7%)      48 (59.3%)                                                   8 (66.7%)      45 (55.6%)     

   Not tested                                                             4 (21.1%)      18 (24.3%)                                                   6 (50.0%)      16 (19.8%)                                                   0 (0%)         22 (27.2%)     

  **Number of metastatic sites**                                                                        0.79 [^b^](#t001fn002){ref-type="table-fn"}                                 0.38 [^a^](#t001fn001){ref-type="table-fn"}                                 0.35

   Median Number of Sites                                                 1.0            2.0            0.48[^a^](#t001fn001){ref-type="table-fn"}    2.0            1.5                                                          2.0            2.0            0.32[^a^](#t001fn001){ref-type="table-fn"}

   **Range**                                                              0--5.0         0--5.0                                                       0--5.0         0--5.0                                                       0--4.0         0--5.0         

  **Response Rate (ORR)** [^d^](#t001fn004){ref-type="table-fn"}                                        0.30 [^b^](#t001fn002){ref-type="table-fn"}                                 0.54 [^b^](#t001fn002){ref-type="table-fn"}                                 0.73[^b^](#t001fn002){ref-type="table-fn"}

   ORR                                                                    9 (47.4%)      23 (34.3%)                                                   5 (45.5%)      27 (36.0%)                                                   5 (41.7%)      27 (36.5%)     

  **Disease Control Rate (DCR)** [^d^](#t001fn004){ref-type="table-fn"}                                 0.58 [^b^](#t001fn002){ref-type="table-fn"}                                 0.15 [^b^](#t001fn002){ref-type="table-fn"}                                 0.86[^b^](#t001fn002){ref-type="table-fn"}

   DCR                                                                    11 (57.9%)     34 (50.7%)                                                   8 (72.7%)      37 (49.3%)                                                   6 (50.0%)      39 (52.7%)     

  **Duration of Immunotherapy**\                                                                        0.87 [^a^](#t001fn001){ref-type="table-fn"}                                 0.50 [^a^](#t001fn001){ref-type="table-fn"}                                 0.54[^a^](#t001fn001){ref-type="table-fn"}
  **(months)** [^e^](#t001fn005){ref-type="table-fn"}                                                                                                                                                                                                           

   Median                                                                 2              3                                                            4.0            3.0                                                          3.0            2.0            

   Range                                                                  1.0--9.0       0--13.0                                                      0--9.0         0--13.0                                                      1.0--9.0       0--13.0        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Wilcoxon rank-sum test;

^b^ Chi square test;

^c^ 9 subjects missing LDH data;

^d^ 16 subjects missing response data;

^e^ 24 subjects with incomplete duration data;

Overall response rate (ORR) = complete response + partial response; disease control rate (DCR) = complete response + partial response + stable disease; TP53^mut^: TP53 pathogenic mutation; TP53^WT^: TP53 wild type; CDKN2A^mut^: CDKN2A pathogenic mutation; CDKN2A^WT^: CDKN2A wild type; Quad^WT^: Quadruple wild type; TTP: Time to progression

Of the 102 patients included in the analysis 93 patients had metastatic disease. Metastases were present in 92.9% of *CDKN2A*^*mut*^, 85.7% of *TP53*^*mut*^ and 91.7% of *Quad*^*WT*^ patients. The presence of these mutations did not affect the sites of disease with exception of a lack of bone metastases in *CDKN2A*^*mut*^ patients and increased lung metastases in the *Quad*^*WT*^ cohort. Cutaneous melanoma was by far the most common subtype of melanoma, while melanoma of unknown primary was far less common with the latter comprising 14.3%, 28.6% and 8.3% in *CDKN2A*^*mut*^, *TP53*^*mut*^ and *Quad*^*WT*^ patients, respectively. In the *CDKN2A*^*mut*^ and *Quad*^*WT*^ cohorts PD-1 inhibitors were the most commonly used agents representing 57.1% and 83.3% of immunotherapies respectively, while in the *TP53*^*mut*^ cohort the most common immunotherapy was ipilumumab (CTLA-4 inhibitor) with 52.4% of patients receiving the CTLA-4 inhibitor. Combination immunotherapies were more commonly used in the *TP53*^*mut*^ cohort as compared to the *CDKN2A*^*mut*^ or *Quad*^*WT*^ cohorts. The demographics of the entire cohort were predominantly Caucasian and male.

Time to progression outcomes {#sec008}
----------------------------

There were no statistically significant differences in TTP identified between the various mutational cohorts ([Fig 2](#pone.0230306.g002){ref-type="fig"}). The median TTP for *CDKN2A*^*mut*^ and *CDKN2A*^*WT*^ were 14.0 months (95% CI: 3.0 months--NE) and 6.0 months (95% CI: 3.0--9.0 months) respectively. The median TTP for *TP53*^*mut*^ and *TP53*^*WT*^ were 8.0 (95% CI: 3.0 months--NE) and 6.0 months (95% CI: 3.0--13.0 months) respectively. Those with *Quad*^*WT*^ had a TTP of 3.5 months (95% CI: 2.0 months--NE) versus 6.0 months (95% CI: 4.0--14.0 months) in those that did not have quadruple wild type. All trends were preserved for TTP in the *CDKN2A*, *TP53* and *Quad*^*WT*^ cohorts at 6 and 12-month intervals ([Table 2](#pone.0230306.t002){ref-type="table"}). The proportion of patients without progression at 12-months for *CDKN2A*^*mut*^ and *CDKN2A*^*WT*^ patients were 60.0% (95% CI: 28.5--81.2%) and 38.3% (95% CI: 27.4--49.0%) respectively. For *TP53*^*mut*^ and *TP53*^*WT*^ the percentage of patients without progression at 12-months were 44.4% (95% CI: 22.5--64.4%) and 40.7% (95% CI: 29.2--51.9%) respectively. The percentage of patients with *Quad*^*WT*^ mutational status without progression at 12-months were 33.3% (95% CI: 10.3--58.8%) versus 42.3% (95% CI: 31.2--53.1%) in those without *Quad*^*WT*^ status. [Fig 2](#pone.0230306.g002){ref-type="fig"} displays TTP graphs for *CDKN2A*, *TP53* and *Quad*^*WT*^ cohorts.

![Time-to-progression by mutation status.](pone.0230306.g002){#pone.0230306.g002}

10.1371/journal.pone.0230306.t002

###### Time to progression by mutation.

![](pone.0230306.t002){#pone.0230306.t002g}

  Mutation           Event/Total   Median Months (95% CI)^KM^   w/o progression (%) at 6-Months   w/o progression (%) at 12-Months
  ------------------ ------------- ---------------------------- --------------------------------- ----------------------------------
  TP53^mut^          12/21         8.0 (3.0-NE)                 55.0 (31.3--73.5%)                44.4 (22.5--64.4%)
  TP53^WT^           48/81         6.0 (3.0--13.0)              44.2 (32.6--55.2%)                40.7 (29.2--51.9%)
  CDKN2A^mut^        7/14          14.0 (3.0-NE)                68.6 (35.9--87.0%)                60.0 (28.5--81.2%)
  CDKN2A^WT^         53/88         6.0 (3.0--9.0)               43.2 (32.2--53.7%)                38.3 (27.4--49.0%)
  Quad^WT^           8/12          3.5 (2.0-NE)                 33.3 (10.3--58.8%)                33.3 (10.3--58.8%)
  Otherwise          52/90         6.0 (4.0--14.0)              48.5 (37.3--58.8%)                42.3 (31.2--53.1%)
  **Overall TTP**:   **60/102**    **6.0 (4.0--13.0)**          **46.6 (36.2--56.3%)**            **41.2 (30.9--51.2%)**

CI: Confidence interval; KM: Kaplan-Meier estimate; NE: Not estimable; TP53^mut^: TP53 pathogenic mutation; TP53^WT^: TP53 wild type; CDKN2A^mut^: CDKN2A pathogenic mutation; CDKN2A^WT^: CDKN2A wild type; Quad^WT^: Quadruple wild type; w/o: Without

Overall survival outcomes {#sec009}
-------------------------

There were no statistically significant differences in OS between the various mutational cohorts ([Fig 3](#pone.0230306.g003){ref-type="fig"}). The median OS for *CDKN2A*^*mut*^ and *CDKN2A*^*WT*^ patients were 41.0 months (95% CI: 17.0--76.0 months) and 57.0 months (95% CI: 26.0 months--NE) respectively. For those with *TP53*^*mut*^ and *TP53*^*WT*^ mutational status the median OS were NE (95% CI: 21.0 months--NE) and 57.0 months (95% CI: 41.0 months--NE) respectively. The median OS for *Quad*^*WT*^ cohort was NE (95% CI: 7.0 months--NE) and those without *Quad*^*WT*^ had a median OS of 57.0 months (95% CI: 41.0 months--NE). The proportion of patients alive at 12 months with *CDKN2A*^*mut*^ and *CDKN2A*^*WT*^ mutational status were 100% (95% CI: 100.0--100.0%) and 74.5% (95% CI: 61.8--83.5%) respectively. The percentage of *TP53*^*mut*^ and *TP53*^*WT*^ patients alive at 12 months were 87.7% (95% CI: 58.8--96.8%) and 75.4% (95% CI: 62.2--84.6%) respectively. The proportion of patients with 12-month OS in the *Quad*^*WT*^ cohort was 70.1% (95% CI: 32.3--89.5%) versus those without *Quad*^*WT*^ was 79.5% (95% CI: 67.6% - 87.4%). The OS outcomes are also shown in [Table 3](#pone.0230306.t003){ref-type="table"}.

![Overall survival by mutation status.](pone.0230306.g003){#pone.0230306.g003}

10.1371/journal.pone.0230306.t003

###### Overall survival from metastatic diagnosis by mutation.

![](pone.0230306.t003){#pone.0230306.t003g}

  Mutation                Event/Total   Median Months (95% CI)^KM^   Survival (%) at 6-Months   Survival (%) at 12-Months
  ----------------------- ------------- ---------------------------- -------------------------- ---------------------------
  TP53^mut^               5/18          NE (21.0-NE)                 94.4 (66.6--99.2%)         87.7 (58.8--96.8%)
  TP53^WT^                21/75         57.0 (41.0-NE)               90.0 (80.2--95.1%)         75.4 (62.2--84.6%)
  CDKN2A^mut^             3/13          41.0 (17.0--76.0)            100.0 (100.0--100.0%)      100.0 (100.0--100.0%)
  CDKN2A^WT^              23/80         57.0 (26.0-NE)               89.5 (80.1--94.6%)         74.5 (61.8--83.5%)
  Quad^WT^                4/11          NE (7.0-NE)                  90.9 (50.8--98.7%)         70.1 (32.3--89.5%)
  Otherwise               22/82         57.0 (41.0-NE)               90.9 (81.9--95.6%)         79.5 (67.6--87.4%)
  **Overall Survival**:   **26/93**     **57.0 (41.0-NE)**           **91.0 (82.7--95.4%)**     **78.2 (67.0--85.9%)**

CI: Confidence interval; KM: Kaplan-Meier estimate; NE: Not estimable; TP53^mut^: TP53 pathogenic mutation; TP53^WT^: TP53 wild type; CDKN2A^mut^: CDKN2A pathogenic mutation; CDKN2A^WT^: CDKN2A wild type; Quad^WT^: Quadruple wild type

Response to immunotherapy {#sec010}
-------------------------

There was no statistically significant difference in overall response rate (ORR) or disease control rate (DCR) between the different mutational cohorts as shown in [Table 1](#pone.0230306.t001){ref-type="table"}. The ORR for *CDKN2A*^*mut*^ and *CDKN2A*^*WT*^ patients were 45.5% and 36.0% respectively (p-value = 0.54), while the DCR for *CDKN2A*^*mut*^ and *CDKN2A*^*WT*^ were 72.7% and 49.3% respectively (p-value = 0.15). The ORR for *TP53*^*mut*^ and *TP53*^*WT*^ patients were 47.4% and 34.3% respectively (p-value = 0.30), while the DCR for *TP53*^*mut*^ and *TP53*^*WT*^ were 57.9% and 50.7% respectively (p-value = 0.58). The ORR for *Quad*^*WT*^ and non-*Quad*^*WT*^ patients were 41.7% and 36.5% respectively (p-value = 0.73). The DCR for *Quad*^*WT*^ patients was 50.0% versus those without quadruple wild type who had a DCR of 52.7% (p-value = 0.86).

Discussion {#sec011}
==========

Despite the negative prognostic significance typically ascribed to loss of *TP53* in malignancies, the data from this study demonstrates no adverse prognostic or predictive significance for mutations of *TP53* or *CDKN2A* in melanoma patients treated with immune checkpoint inhibitor therapy. The lack of deleterious effect from mutations in genes controlling cell cycle regulators is further supported by consistency across mutational cohorts in regards to TTP, 12-month OS, DCR and ORR. While not statistically significant, *CDKN2A*^*mut*^ patients appeared to have a trend towards improved DCR and TTP. However, a larger cohort would be needed to investigate whether clinical outcomes are truly enhanced in patients with *CDKN2A*^*mut*^.

The devaluation of cell cycle regulators with immune checkpoint inhibitor therapy is likely explained by the mechanism in which cytotoxic T cells induce cell death. Chemotherapy primarily induces apoptosis in malignant cells via cellular stress and the intrinsic caspase pathway. For instance, many chemotherapy treatments will induce DNA damage, which will in turn signal cell cycle regulators such as *TP53* and *CDKN2A* to activate the intrinsic caspase pathway to induce apoptosis \[[@pone.0230306.ref022]--[@pone.0230306.ref024]\]. The lethality of immune checkpoint inhibitors is derived primarily from the activation of cytotoxic T cells, which induce apoptosis through granzyme \[[@pone.0230306.ref025]\]. Granzyme is a serine protease that enters the cytoplasm via perforin and directly activates the caspase pathway independent of cell cycle regulators and induces apoptosis. Additionally, activation of the adaptive immune system will also initiate the extrinsic caspase pathway via death ligands such as tumor necrosis factor (TNF) super family and FasL. Therefore, the cytotoxic effects activated by the adaptive immune system do not appear to be driven by the internal machinery of the cell cycle and its regulators. Rather, T cell recognition of tumor cells via tumor epitopes and immune activating markers that initiates the introduction of granzyme are the more relevant drivers for checkpoint inhibitors. The clinical findings from this small retrospective study support the preclinical rationale that immune checkpoints are not adversely affected by the absence of cell cycle regulators. In addition, these findings are further supported by a previous study that did not show an adverse impact of TP53 mutations on clinical outcomes when patients were treated with ipilimumab \[[@pone.0230306.ref021]\].

It is more difficult to interpret the findings of the *Quad*^*WT*^ cohort given that this cohort includes a diverse collection of mutations. A number of pathogenic mutations were identified in the *Quad*^*WT*^ group including: *KIT* (n = 3), *BRAF*^*non-V600*^ (n = 2), *APC* (n = 1), *CTNNB1* (n = 1), *HRAS* (n = 1) and *STK11* (n = 1). Similar to the *CDKN2A*^*mut*^ and *TP53*^*mut*^ cohorts there was no statistically significant difference in clinical outcomes observed in this study. However, there was a trend towards worsened median TTP in this patient cohort (3.5 months vs 6.0 months). However, other clinical outcomes including ORR, DCR and 12-month OS were similar between *Quad*^*WT*^ cohort and the non-*Quad*^*WT*^ cohorts. Given the small size of this cohort (n = 12) and heterogeneous genotype of this cohort conclusions cannot be drawn.

The small size of the study cohort and the retrospective nature of this study are limitations of this exploratory study. Because of the limited sample size the effect of co-mutations on clinical outcomes could not be analyzed with this cohort of patients. Additionally there was heterogeneous use of PD-1 inhibitors and CTLA-4 inhibitors between mutational cohorts. For instance, the *TP53*^*mut*^ cohort and non-*Quad*^*WT*^ cohort both had a higher proportion of ipilimumab use. Given that PD-1 inhibitors are known to have higher response rates and improved clinical outcomes compared to CTLA-4 inhibitors this may have underestimated the benefit of checkpoint inhibitors in these cohorts. However, despite the difference in treatment modalities there appeared to be consistency across clinical outcomes with similar OS, TTP, ORR and DCR results. Additionally, the *TP53*^*mut*^ and non-*Quad*^*WT*^ cohorts did not appear to fare any worse despite the higher utilization of ipilimumab.

This exploratory study suggests that immune checkpoint inhibitors are able to function at least as well in the presence of *CDKN2A* or *TP53* pathogenic mutations. The lack of clear driver mutations such as *CDKN2A*, *TP53*, *NRAS* or *BRAF*^*V600*^ mutations (*Quad*^*WT*^) also did not seem to significantly impact clinical outcomes in this cohort of patients. While the role for *CDKN2A* and *TP53* are integral to oncogenesis of melanoma and escape from senescence these mutations do not appear to have a significant deleterious effect on prognosis when immune checkpoint inhibitors are used for therapy.

Given the increasing frequency with which large gene mutation panels are being ordered by practicing clinicians, it is necessary to analyze the significance of common mutations in a given cancer type in order to both focus the clinician on relevant findings, and help them ignore irrelevant ones. Researchers with access to large databases of clinical and genomic findings should systematically analyze the association between common genetic events and clinical outcomes. As in this case, such retrospective studies are exploratory and can help guide larger prospective studies.

Methods {#sec012}
=======

Study population/study design {#sec013}
-----------------------------

This is a retrospective study which was approved by Mayo Clinic IRB(16--005168). No consent was needed as information was obtain anonymously. This study was conducted in accordance with principles for human experimentation as defined in the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines. No participating physicians have conflicts of interest to declare. The Mayo Clinic IRB waived the requirement for informed consent since the data was analyzed anonymously. Patients were identified from all three Mayo Clinic campuses (Minnesota, Arizona and Florida). Patients with a diagnosis of metastatic or unresectable cutaneous melanoma or melanoma of unknown primary whose tumors were analyzed with our 50 gene Solid Tumor Targeted Cancer Gene Panel were included. Patients who received an immune checkpoint inhibitor at any point during their treatment course were included. However, data associated with the first immunotherapy regimen and overall patient outcomes were evaluated for this analysis. Response to targeted therapy, chemotherapy and subsequent lines of immunotherapy treatments were collected but are not the focus of this study. This study allowed for treatment with cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors, PD-1 inhibitors, or combinations that included either a PD-1 inhibitor or CTLA-4 inhibitor.

The objective of this study is to investigate the impact of the presence of *CDKN2A* mutations (*CDKN2A*^*mut*^), *TP53* mutations (*TP53*^*mut*^) and quadruple wild type (*Quad*^*WT*^) mutational status on clinical outcomes in patients who received immune checkpoint inhibitors. Patients who did not carry *TP53*, *CDKN2A*, *NRAS* or *BRAF*^*v600*^ mutations were termed *Quad*^*WT*^. The primary endpoint measured was median time-to-progression (TTP) with secondary endpoints including the percentage of participants without progression at 6 and 12 months, median overall survival (OS), OS at 6 and 12 months, disease control rate (DCR) and overall response rate (ORR) to immunotherapy. Response rates were assessed using available CT or MRI imaging and their associated reports. Calculations were based on the best overall response using the immune related response criteria (irRC) and were categorized as complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Pathologic tumor characteristics, patient demographic and clinical details were also collected by chart review.

Genomic profiling {#sec014}
-----------------

The Solid Tumor Targeted Cancer Gene Panel is a 50 gene panel that evaluated the following genes: *ABL1*, *AKT1*, *ALK*, *APC*, *ATM*, *BRAF*, *CDH11*, *CKDN2A*, *CSF1R*, *CTNNB1*, *EGFR*, *ERBB2*, *ERBB4*, *EZH2*, *FBXW7*, *FGFR1*, *FGFR2*, *FGFR3*, *FLT3*, *GNA11*, *GNAQ*, *GNAS*, *HNF1A*, *HRAS*, *IDH1*, *IDH2*, *JAK2*, *JAK3*, *KDR*, *KIT*, *KRAS*, *MET*, *MLH1*, *MPL*, *NOTCH1*, *NPM1*, *NRAS*, *PDGFRA*, *PIK3CA*, *PTEN*, *PTPN11*, *RB1*, *RET*, *SMAD4*, *SMARCB1*, *SMO*, *SRC*, *STK11*, *TP53* and *VHL*. This is a laboratory-developed test using Research Use Only reagents. Extracted DNA from the clinical specimen is fragmented, adapter ligated, and a sequence library of fragments is prepared using a custom capture hybridization method. Individual patient samples are indexed for identification and the library is sequenced on an Illumina platform. Sequence data are processed through the Mayo Clinic Clinical Genome Sequencing Lab bioinformatics pipeline and a variant call file is generated for final analysis and reporting(Unpublished Mayo method). This testing is clinically available through Mayo Clinic.

Statistics {#sec015}
----------

Patient characteristics were compared between mutation statuses (*TP53*^*mut*^ versus *TP53* wild type \[*TP53*^*WT*^\], *CDKN2A*^*mut*^ versus CDKN2A wild type \[*CDKN2A*^*WT*^\] and *Quad*^*WT*^ versus non-*Quad*^*WT*^). Wilcoxon rank-sum compared non-normally distributed continuous data and chi-square tests compared categorical data. Nonparametric survival analysis was used to model TTP and OS. TTP was defined as the time from first line immunotherapy date until date of progression. A patient's progression time was censored if they received subsequent treatment, were lost to follow-up, or death occurred before known progression. OS was defined as the time from metastatic diagnosis date until date of death. Survival time was censored when patients were lost to follow-up. Kaplan-Meier (KM) method was used to estimate event rates, median time and 95% confidence intervals. Median TTP and OS estimates were not estimable (NE) where rates were greater than 50% at the last time point in the cohort. Log-rank test was used to compare TTP and OS event rates between mutation statuses. *P* values ≤ .05 were considered statistically significant. Analyses were performed in SAS Statistical Software 9.4 (SAS Institute, Cary, NC).

Supporting information {#sec016}
======================

###### Genotypes *CDKN2A*, *TP53* and quadruple wild type cohorts.

(DOCX)

###### 

Click here for additional data file.
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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2\. Has the statistical analysis been performed appropriately and rigorously?
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3\. Have the authors made all data underlying the findings in their manuscript fully available?
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: DeLeon and colleagues have undertaken a retrospective single centre review of the prognostic and predictive impact of CDKN2A and p53 mutations on TTP/OS and response in immunotherapy treated patients.

The analysis suggests no impact on of these mutations.

I have a number of suggestions which the authors may consider

1\) Given the impact of clinicopathological factors on outcome (eg Liver mets, LDH, primary histology) these associations with mutation and outcome should be considered

2\) Combining single agent ipilimumab with anti-PD1 based therapy (and even targeted therapy) creates significant heterogeneity. Suggest PD1 based vs ipi alone

Reviewer \#2: The manuscript by DeLeon et al addresses an important clinical question as to whether somatic mutations in cell cycle regulators (TP53 and CDKN2A) are predictive of outcomes in melanoma patients treated with checkpoint inhibitor immunotherapy. Although the results show no significant associations, the findings are useful for clinicians in that mutations in either TP53 or CDKN2A need not guide checkpoint inhibitor treatment decisions.

The authors acknowledge that the sample size (n=102 patients) is a major limiting factor that likely influences the study outcomes, however, this will hopefully prompt other melanoma researchers to investigate using larger datasets that will settle the debate.

It would also be interesting in future to delineate between types of checkpoint inhibitors (antiPD-1, antiCTLA-4 or combination) as well as mutation type (likely gain of function vs. loss of function) not possible in this study with low samples sizes for each category.

Minor revisions:

• The word "somatic" mutations should be used in the title and abstract to distinguish from germline mutations which are common in CDKN2A in melanoma.

• When you quote the mutation frequencies as a range it would be clearer to mention you've looked at both the Hodis and TCGA datasets.

• "CDKN2A and TP53 mutations were present together" would be better written as "co-occur."

• "BRAF, NRAS, CDKN2A and TP53 mutations were absent" would be better written as QuadWT (BRAF, NRAS, CDKN2A and TP53) accounted for 8.3%-32.2% of cases.

• "demonstrated in multiple other malignancies" needs a reference.

• "ipilumumab" misspelled and first time appears should mention it targets CTLA-4.

• Consistency in PD1 or PD-1.

• NE should be defined the first time it appears in the text.

• Will the full mutation datasets be made available i.e. the specific single nucleotide variants, is it in the coding or non-coding region? synonymous or non-synonymous? Missense or nonsense etc. How do you know it's "pathogenic?"

• Why is NF1 not included in the panel? This gene is altered in up to 20% of melanoma cases and BRAF/NRAS/NF1 triple wild-type patients are regarded as a difficult category to treat.

• Why not show your BRAF and NRAS data? You mention in the introduction that the literature is nuanced regarding mutational status vs clinical outcomes for checkpoint inhibitors in melanoma. You have solid numbers in these categories -- would your data not help resolve this?
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Matteo Carlino

Reviewer \#2: Yes: Jessamy Tiffen

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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We thank you and the reviewers for the thorough evaluation of our manuscript and the thoughtful comments. In response to the reviewers' comments, we are submitting a revised manuscript entitled "Assessment of Clinical Outcomes with Immune Checkpoint Inhibitor Therapy in Melanoma Patients with Somatic CDKN2A and TP53 pathogenic mutations." We have made appropriate edits to the manuscript, which are highlighted, and address each comment point by point as below in bold.

Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

Response: Once the manuscript has been accepted for publication, we will provide data requested. We will include the data spread sheets and statistics. If there is specific data that is required, I will attempt to obtain but I have included what was used for this project.

Reviewer \#1: DeLeon and colleagues have undertaken a retrospective single centre review of the prognostic and predictive impact of CDKN2A and p53 mutations on TTP/OS and response in immunotherapy treated patients.

The analysis suggests no impact on of these mutations.

I have a number of suggestions which the authors may consider

1\) Given the impact of clinicopathological factors on outcome (eg Liver mets, LDH, primary histology) these associations with mutation and outcome should be considered

Response: Thank you very much for your overall favorable impression of our efforts to investigate treatments and outcomes in this rare disease, and for your comments. We agree that these factors do impact the outcomes of patients with this disease. Table 1. represents the patient\'s baseline characteristics which did include liver mets and LDH. In our data set these clinicopathological factors did not meet statistical significance. They did not play a role in outcomes of our patients. This is likely the result of our study being under powered to determine each factors significance. If we examine a larger population, it would be interesting to see if these play a role. Unfortunately, given the size of our study I\'m unable to include more data related to these factors.

2\) Combining single agent ipilimumab with anti-PD1 based therapy (and even targeted therapy) creates significant heterogeneity. Suggest PD1 based vs ipi alone

Response: Agreed, adding more agents does create more heterogeneity within treatment paradigms in leads a question of which agent is the most impact full. In our study we attempted to treat patients with standard of care or standard practice within our center. Table 1. Shows that there is no statistical significance and/or difference between the use of these agents in the setting of these mutations. Again, this is likely from our limitation of sample size and power. If this study could be completed on a larger scale there could potentially be a statistical difference identified. At this time given her sample size I\'m unable to further expound on this data.

Reviewer \#2: The manuscript by DeLeon et al addresses an important clinical question as to whether somatic mutations in cell cycle regulators (TP53 and CDKN2A) are predictive of outcomes in melanoma patients treated with checkpoint inhibitor immunotherapy. Although the results show no significant associations, the findings are useful for clinicians in that mutations in either TP53 or CDKN2A need not guide checkpoint inhibitor treatment decisions.

The authors acknowledge that the sample size (n=102 patients) is a major limiting factor that likely influences the study outcomes, however, this will hopefully prompt other melanoma researchers to investigate using larger datasets that will settle the debate.

It would also be interesting in future to delineate between types of checkpoint inhibitors (antiPD-1, antiCTLA-4 or combination) as well as mutation type (likely gain of function vs. loss of function) not possible in this study with low samples sizes for each category.

Minor revisions:

• The word "somatic" mutations should be used in the title and abstract to distinguish from germline mutations which are common in CDKN2A in melanoma.

Response: Thank you very much for your overall favorable impression of our efforts to investigate treatments and outcomes in this disease, and for your comments. We agree this is an important term to delineate so we added and addressed this.

• When you quote the mutation frequencies as a range it would be clearer to mention you've looked at both the Hodis and TCGA datasets.

Response: We attempted to make this clear for better understanding for the readers. We edited and addressed this.

• "CDKN2A and TP53 mutations were present together" would be better written as "co-occur."

Response: Edited and added.

• "BRAF, NRAS, CDKN2A and TP53 mutations were absent" would be better written as QuadWT (BRAF, NRAS, CDKN2A and TP53) accounted for 8.3%-32.2% of cases.

Response: Edited and added.

• "demonstrated in multiple other malignancies" needs a reference.

Response: Added a reference.

• "ipilumumab" misspelled and first time appears should mention it targets CTLA-4.

Response: Edited and corrected.

• Consistency in PD1 or PD-1.

Response: Corrected.

• NE should be defined the first time it appears in the text.

Response: This was a formatting technicality. We have now corrected it.

• Will the full mutation datasets be made available i.e. the specific single nucleotide variants, is it in the coding or non-coding region? synonymous or non-synonymous? Missense or nonsense etc. How do you know it's "pathogenic?"

Response: If the publication is accepted we do have variants included in our data sets such as: "TP53:c.722C\>T:p.S241F(Ser241Phe):MUT" and "CDKN2A 21971164 A \> G (benign)/ CDKN2A 21971186 G \> A (PATHOGENIC)/CDKN2A 21971141 C \> G (\"unknown\" in workbench)

CDKN2A 21971164 A \> G (benign)." We will include that will inform our readers if the variant is pathogenic according to our NGS.

• Why is NF1 not included in the panel? This gene is altered in up to 20% of melanoma cases and BRAF/NRAS/NF1 triple wild-type patients are regarded as a difficult category to treat.

Response: This is a wonderful question. We used a 50 gene panel with pre-specified genes which were determined by Mayo Clinic Lab. The panel is not specifically for melanoma but for solid tumors and unfortunately the 50 gene panel did not include NF1. Mayo clinic laboratory created the gene panel and I do not have access to the data on why they chose the specific genes to be included on that panel. It is a wonderful thought and should be evaluated further in a future study.

• Why not show your BRAF and NRAS data? You mention in the introduction that the literature is nuanced regarding mutational status vs clinical outcomes for checkpoint inhibitors in melanoma. You have solid numbers in these categories -- would your data not help resolve this?

Response: This is a challenging question. We wanted to make the focus of our study on CDKN2A and p53 specifically to answer the question if these mutations play a role in response to therapy. We felt that if we included BRAF it would take away from our focus in this manuscript. Our data sets will include the BRAF and NRAS mutations. In a future study looking less specifically at CDKN2A and p53 we may include our data.
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With kind regards,

Nikolas K. Haass, MD/PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

One important requirement is that the full datasets will need to be deposited to a public repository, in keeping with the PLOS Data policy.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?
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Dear Dr. Almquist:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.
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PLOS ONE Editorial Office Staff
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Prof Nikolas K. Haass

Academic Editor
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